Journal ArticleDOI
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert,Sibylle Loibl,Aurelia Noske,Marc Roller,Berit Maria Müller,Martina Komor,Jan Budczies,Silvia Darb-Esfahani,Ralf Kronenwett,Claus Hanusch,Christian von Törne,Wilko Weichert,Knut Engels,Christine Solbach,Iris Schrader,Manfred Dietel,Gunter von Minckwitz +16 more
Reads0
Chats0
TLDR
The presence of tumor-associated lymphocytes in breast cancer is a new independent predictor of response to anthracycline/taxane neoadjuvant chemotherapy and provides useful information for oncologists to identify a subgroup of patients with a high benefit from this type of chemotherapy.Abstract:
PURPOSE Preclinical data suggest a contribution of the immune system to chemotherapy response. In this study, we investigated the prespecified hypothesis that the presence of a lymphocytic infiltrate in cancer tissue predicts the response to neoadjuvant chemotherapy. METHODS We investigated intratumoral and stromal lymphocytes in a total of 1,058 pretherapeutic breast cancer core biopsies from two neoadjuvant anthracycline/taxane-based studies (GeparDuo, n = 218, training cohort; and GeparTrio, n = 840, validation cohort). Molecular parameters of lymphocyte recruitment and activation were evaluated by kinetic polymerase chain reaction in 134 formalin-fixed, paraffin-embedded tumor samples. Results In a multivariate regression analysis including all known predictive clinicopathologic factors, the percentage of intratumoral lymphocytes was a significant independent parameter for pathologic complete response (pCR) in both cohorts (training cohort: P = .012; validation cohort: P = .001). Lymphocyte-predominant breast cancer responded, with pCR rates of 42% (training cohort) and 40% (validation cohort). In contrast, those tumors without any infiltrating lymphocytes had pCR rates of 3% (training cohort) and 7% (validation cohort). The expression of inflammatory marker genes and proteins was linked to the histopathologic infiltrate, and logistic regression showed a significant association of the T-cell-related markers CD3D and CXCL9 with pCR. CONCLUSION The presence of tumor-associated lymphocytes in breast cancer is a new independent predictor of response to anthracycline/taxane neoadjuvant chemotherapy and provides useful information for oncologists to identify a subgroup of patients with a high benefit from this type of chemotherapy.read more
Citations
More filters
Journal ArticleDOI
The immune contexture in human tumours: impact on clinical outcome
Wolf H. Fridman,Franck Pagès,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Jérôme Galon +5 more
TL;DR: In this Opinion article, the context-specific nature of infiltrating immune cells can affect the prognosis of patients is discussed.
Journal ArticleDOI
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
TL;DR: Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.
Journal ArticleDOI
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch,E P Winer,A S Coates,R. D. Gelber,M Piccart-Gebhart,B. Thürlimann,H.-J. Senn,Kathy S. Albain,Fabrice Andre,Jonas Bergh,Hervé Bonnefoi,Denisse Bretel-Morales,Harold J. Burstein,Fatima Cardoso,M. Castiglione-Gertsch,Alan S. Coates,Marco Colleoni,Alberto Costa,Giuseppe Curigliano,Nancy E. Davidson,Angelo Di Leo,Bent Ejlertsen,John F. Forbes,Richard D. Gelber,Michael Gnant,Aron Goldhirsch,Pamela J. Goodwin,Paul E. Goss,Jay R. Harris,Daniel F. Hayes,Clifford A. Hudis,James N. Ingle,Jacek Jassem,Zefei Jiang,Per Karlsson,Sibylle Loibl,Monica Morrow,Moïse Namer,C. Kent Osborne,Ann H. Partridge,Frédérique Penault-Llorca,Charles M. Perou,Martine Piccart-Gebhart,Kathleen I. Pritchard,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Z Shao,Ian E. Smith,Beat Thürlimann,Masakazu Toi,Andrew Tutt,Michael Untch,Giuseppe Viale,Toru Watanabe,Nicholas Wilcken,Eric P. Winer,William C. Wood +57 more
TL;DR: The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy.
Journal ArticleDOI
Immunogenic Cell Death in Cancer Therapy
TL;DR: It is postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies and its subversion by pathogens.
Journal ArticleDOI
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton,Mairéad G McNamara,Bostjan Seruga,Francisco E. Vera-Badillo,Priya Aneja,Alberto Ocaña,Raya Leibowitz-Amit,Guru Sonpavde,Jennifer J. Knox,Ben Tran,Ian F. Tannock,Eitan Amir +11 more
TL;DR: A high NLR is associated with an adverse OS in many solid tumors, and its addition to established prognostic scores for clinical decision making warrants further investigation.
References
More filters
Journal ArticleDOI
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang,Jose R. Conejo-Garcia,Dionyssios Katsaros,Phyllis A. Gimotty,Marco Massobrio,Giorgia Regnani,Antonis Makrigiannakis,Heidi J. Gray,Katia Schlienger,Michael N. Liebman,Stephen C. Rubin,George Coukos +11 more
TL;DR: The presence of intratumoral T cells correlates with improved clinical outcome in advanced ovarian carcinoma and was associated with increased expression of interferon-gamma, interleukin-2, and lymphocyte-attracting chemokines within the tumor.
Journal ArticleDOI
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more
TL;DR: A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
Journal ArticleDOI
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Bernard Fisher,John Bryant,Norman Wolmark,Eleftherios P. Mamounas,Ann J. Brown,Edwin R. Fisher,D L Wickerham,Mirsada Begovic,Arthur DeCillis,André Robidoux,Richard G. Margolese,A B Cruz,James L. Hoehn,A W Lees,Nikolay V. Dimitrov,Harry D. Bear +15 more
TL;DR: Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology.
Journal ArticleDOI
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Franck Pagès,Anne Berger,Matthieu Camus,Fátima Sánchez-Cabo,Anne Costes,Robert Molidor,Bernhard Mlecnik,Amos Kirilovsky,Malin Nilsson,Diane Damotte,Tchao Meatchi,Patrick Bruneval,Paul-Henri Cugnenc,Zlatko Trajanoski,Wolf H. Fridman,Jérôme Galon +15 more
TL;DR: Signs of an immune response within colorectal cancers are associated with the absence of pathological evidence of early metastatic invasion and with prolonged survival.
Journal ArticleDOI
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi,Stewart J. Anderson,Harry D. Bear,Charles E. Geyer,Morton S. Kahlenberg,André Robidoux,Richard G. Margolese,James L. Hoehn,Victor G. Vogel,Shaker R. Dakhil,Deimante Tamkus,Karen M. King,Eduardo R. Pajon,Mary Johanna Wright,Jean Robert,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +17 more
TL;DR: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy and showed that the addition of preoperative taxanes to AC improves response.
Related Papers (5)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado,Carsten Denkert,Sandra Demaria,Nicolas Sirtaine,Frederick Klauschen,Giancarlo Pruneri,Stephan Wienert,G. Van den Eynden,Frederick L. Baehner,Frédérique Penault-Llorca,E. A. Perez,E. A. Thompson,William Fraser Symmans,Andrea L. Richardson,Jane E. Brock,Carmen Criscitiello,Helen Bailey,Michail Ignatiadis,Giuseppe Floris,Joseph A. Sparano,Zuzana Kos,Torsten O. Nielsen,David L. Rimm,Kimberly H. Allison,Jorge S. Reis-Filho,Sibylle Loibl,Christos Sotiriou,Giuseppe Viale,Sunil S. Badve,Sylvia Adams,Karen Willard-Gallo,Sherene Loi +31 more